Results 81 to 90 of about 34,537 (182)

Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure

Gut and Liver, 2014
Background/AimsWe investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies.Methods : Seventeen patients who failed to achieve virological ...
doaj   +1 more source

SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca, Luca Maddaloni, Alessandra D'Auria, Matteo Fracella, Ginevra Bugani, Carmen Falvino, Valentina Baccolini, Giuseppe Migliara, Francesca Aloisi, Letizia Santinelli, Enrico Palermo, Luca Bortolani, Alessandro Lazzaro, Giancarlo Ceccarelli, Ombretta Turriziani, Claudio Maria Mastroianni, Guido Antonelli, Gabriella d'Ettorre, Carolina Scagnolari   +18 more
wiley   +1 more source

Renal Tubular Acidosis and Osteomalacia, Possibly Associated with Tenofovir

Turkish Journal of Nephrology, 2019
Tenofovir is one of the first-line new generation antiviral agents commonly used in chronic hepatitis B treatment. While being considered an effective and safe treatment, the most important side effect known is nephrotoxicity.
Faruk ELYİĞİT, Bengü ERKUL, Hakan YARKICI, Handan ARLI, Lütfiye Bilge ÇALIŞKAN, Harun AKAR   +5 more
doaj  

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles [PDF]

Clinical and Molecular Hepatology, 2022
Hung-Yao Lin, Tai-Chung Tseng
doaj   +1 more source

HIV and CKD in the Tenofovir Era: A Prospective Parallel-Group Cohort Study From Tanzania

Kidney Medicine
Rationale & Objective: Longitudinal research on chronic kidney disease (CKD) in sub-Saharan Africa is sparse, especially among people living with HIV (PLWH).
Nicholas L.S. Roberts, Salama Fadhil, Megan Willkens, Grace Ruselu, Bernard Desderius, Said Kanenda, Ladius Rudovick, Bazil B. Kavishe, Serena P. Koenig, Sri Lekha Tummalapalli, Myung Hee Lee, Robert N. Peck   +11 more
doaj   +1 more source

Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
This graphical summary illustrates the multiorgan therapeutic landscape for Type 2 diabetes mellitus (T2D), integrating molecular pathogenesis with modern treatment strategies. It depicts how current interventions, including SGLT2 inhibitors, GLP‐1 receptor agonists, and insulin secretagogues, target key organs—kidney, pancreas, gastrointestinal tract,
Shinuan Fei, Xiyue Xiong, Lu Zhang, Jian Zhang, Lawrence W. C. Chan, Hong Jiang, Qingqing Xiong, Changtao Hu, Jie Chen, Sijun Yang   +9 more
wiley   +1 more source

Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis

Frontiers in Pharmacology
Background and aimsThe effects of Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) on lipid profiles have been observed in chronic hepatitis B (CHB) treatment.
Yuan-Hai Zhou, Yuan-Hai Zhou, Nan Cai, Nan Cai, Yu-Xin Chen, Yu-Xin Chen, Yong-Lu Su, Yong-Lu Su, Peng Hu, Peng Hu, Peng Hu   +10 more
doaj   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

A Systematic Review of Published Physiologically Based Pharmacokinetic Models for Drug Excretion Into Human Breastmilk: Knowledge Gaps and Opportunities to Optimize Reporting and Modeling Practices

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) modeling is increasingly used to predict infant exposure to medications via breast milk. Existing guidance on reporting of PBPK modeling analyses is unstructured and nonbinding to researchers. We evaluated reporting practices and modeling approaches in published PBPK modeling studies.
Joshua Kiptoo, Davies Otieno, Kenta Yoshida, Neel Deferm, Aida Nakayiwa Kawuma, Francis Williams Ojara, Adeniyi Olagunju, Jackson K. Mukonzo, Catriona Waitt   +8 more
wiley   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source